Confirmation of Safety of COVID 19 mRNA Vaccination for Cancer Patients

Patients in the active phase of treatment for cancer are a population at risk of coronavirus disease 19 COVID 19 with poor prognosis. While a majority of patients treated for cancer expressed their will to be vaccinated as early as December 2020 in a French survey, no data were available in terms of vaccine efficacy and tolerance, because they were excluded from initial registration trials. Several clinical facilities aimed to assess the safety and immunogenicity of the BNT162b2 Pfizer–BioNTech vaccine in patients with cancer. In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. However, the anti SARS CoV 2 immune response was lower in patients with solid tumors who were vaccinated a second dose of BNT162b2 vaccine than in healthy individuals. These data support prioritization of patients with cancer for an early day 21 second dose of the BNT162b2 vaccine. Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi "Confirmation of Safety of COVID-19 mRNA Vaccination for Cancer Patients" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd42563.pdf Paper URL: https://www.ijtsrd.commedicine/other/42563/confirmation-of-safety-of-covid19-mrna-vaccination-for-cancer-patients/takuma-hayashi